Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Down 56.7% in February

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 191,156 shares, a drop of 56.7% from the February 12th total of 441,371 shares. Based on an average daily volume of 435,180 shares, the days-to-cover ratio is currently 0.4 days. Approximately 9.6% of the shares of the company are sold short. Approximately 9.6% of the shares of the company are sold short. Based on an average daily volume of 435,180 shares, the days-to-cover ratio is currently 0.4 days.

Analysts Set New Price Targets

Several brokerages recently issued reports on MBRX. Roth Mkm restated a “buy” rating on shares of Moleculin Biotech in a research report on Monday, December 15th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective (up from $4.00) on shares of Moleculin Biotech in a research report on Thursday, December 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Moleculin Biotech has a consensus rating of “Moderate Buy” and an average price target of $61.00.

Hedge Funds Weigh In On Moleculin Biotech

A hedge fund recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Moleculin Biotech Trading Down 0.5%

NASDAQ MBRX traded down $0.01 during trading on Friday, hitting $2.04. 147,650 shares of the company’s stock were exchanged, compared to its average volume of 284,870. The company has a market cap of $4.15 million, a PE ratio of -0.06 and a beta of 1.73. Moleculin Biotech has a fifty-two week low of $1.79 and a fifty-two week high of $33.00. The stock’s 50 day moving average price is $3.60 and its two-hundred day moving average price is $7.41.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.